Caspase-1 Inhibition Ameliorates Photoreceptor Damage Following Retinal Detachment by Inhibiting Microglial

Yumei Cao1, Lei Qiao2, Yingying Song1

  • 1Department of Ophthalmology, The Affiliated Xuzhou Municipal Hospital of Xuzhou Medical University, Xuzhou First People's Hospital, Eye Disease Prevention and Treatment Institute of Xuzhou, Xuzhou, China; Xuzhou Medical University, Xuzhou, China.

Insights

Microglial pyroptosis drives early retinal detachment (RD) inflammation. VX-765, a caspase-1 inhibitor, reduced this inflammation and protected photoreceptors, suggesting a potential therapy for RD.

Area of Science:

  • Ophthalmology
  • Neuroscience
  • Immunology

Background:

  • Retinal detachment (RD) is a serious condition impacting vision.
  • Activated microglia contribute to photoreceptor cell death following RD.
  • The role of microglial pyroptosis in early RD pathology remains unclear.

Purpose of the Study:

  • To investigate microglial pyroptosis in early retinal detachment.
  • To evaluate the therapeutic potential of VX-765, a caspase-1 inhibitor, in an RD model.
  • To determine if VX-765 affects microglial pyroptosis and photoreceptor survival.

Main Methods:

  • Utilized rat models of retinal detachment.
  • Employed immunofluorescence co-staining and flow cytometry to detect pyroptosis.
  • Administered VX-765 and assessed microglial phenotype, migration, pyroptosis, and photoreceptor integrity (ONL thickness, H&E, TEM).

Main Results:

  • Pyroptosis was confirmed in microglia (IBA1+, P2RY12+) expressing gasdermin D N-terminal (GSDMD-N) in early RD.
  • VX-765 treatment shifted microglia to an M2 phenotype, reduced migration, and inhibited pyroptosis.
  • VX-765 administration increased outer nuclear layer (ONL) thickness and improved photoreceptor structure.

Conclusions:

  • Microglial pyroptosis is an early inflammatory process in retinal detachment.
  • VX-765 demonstrates neuroprotective effects on photoreceptors by targeting microglial pyroptosis.
  • VX-765 represents a potential therapeutic strategy for treating retinal detachment.